Literature DB >> 18246122

MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer.

M Garofalo1, C Quintavalle, G Di Leva, C Zanca, G Romano, C Taccioli, C G Liu, C M Croce, G Condorelli.   

Abstract

To define novel pathways that regulate susceptibility to tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) in non-small cell lung cancer (NSCLC), we have performed genome-wide expression profiling of microRNAs (miRs). We show that in TRAIL-resistant NSCLC cells, levels of different miRs are increased, and in particular, miR-221 and -222. We demonstrate that these miRs impair TRAIL-dependent apoptosis by inhibiting the expression of key functional proteins. Indeed, transfection with anti-miR-221 and -222 rendered CALU-1-resistant cells sensitive to TRAIL. Conversely, H460-sensitive cells treated with -221 and -222 pre-miRs become resistant to TRAIL. miR-221 and -222 target the 3'-UTR of Kit and p27(kip1) mRNAs, but interfere with TRAIL signaling mainly through p27(kip1). In conclusion, we show that high expression levels of miR-221 and -222 are needed to maintain the TRAIL-resistant phenotype, thus making these miRs as promising therapeutic targets or diagnostic tool for TRAIL resistance in NSCLC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18246122     DOI: 10.1038/onc.2008.6

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  131 in total

Review 1.  Implication of microRNAs in drug resistance for designing novel cancer therapy.

Authors:  Fazlul H Sarkar; Yiwei Li; Zhiwei Wang; Dejuan Kong; Shadan Ali
Journal:  Drug Resist Updat       Date:  2010-03-17       Impact factor: 18.500

2.  MicroRNA profiles of drug-resistant myeloma cell lines.

Authors:  Reinhold Munker; Chang-Gong Liu; Cristian Taccioli; Hansjuerg Alder; Nyla Heerema
Journal:  Acta Haematol       Date:  2010-03-31       Impact factor: 2.195

Review 3.  Missing link between microRNA and prostate cancer.

Authors:  Balraj Singh Gill; Jimi Marin Alex; Sanjeev Kumar
Journal:  Tumour Biol       Date:  2016-01-28

4.  Anti-microRNA-222 (anti-miR-222) and -181B suppress growth of tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal.

Authors:  Yuanzhi Lu; Satavisha Roy; Gerard Nuovo; Bhuvaneswari Ramaswamy; Tyler Miller; Charles Shapiro; Samson T Jacob; Sarmila Majumder
Journal:  J Biol Chem       Date:  2011-10-18       Impact factor: 5.157

Review 5.  Deregulation of microRNA expression in thyroid neoplasias.

Authors:  Pierlorenzo Pallante; Sabrina Battista; Giovanna Maria Pierantoni; Alfredo Fusco
Journal:  Nat Rev Endocrinol       Date:  2013-11-19       Impact factor: 43.330

6.  High stability of microRNAs in tissue samples of compromised quality.

Authors:  Lorena Peiró-Chova; María Peña-Chilet; José Antonio López-Guerrero; José Luis García-Giménez; Elisa Alonso-Yuste; Octavio Burgues; Ana Lluch; Jaime Ferrer-Lozano; Gloria Ribas
Journal:  Virchows Arch       Date:  2013-10-03       Impact factor: 4.064

Review 7.  In vivo delivery of miRNAs for cancer therapy: challenges and strategies.

Authors:  Yunching Chen; Dong-Yu Gao; Leaf Huang
Journal:  Adv Drug Deliv Rev       Date:  2014-05-22       Impact factor: 15.470

Review 8.  MicroRNA signature and regulatory functions in the endometrium during normal and disease states.

Authors:  Qun Pan; Nasser Chegini
Journal:  Semin Reprod Med       Date:  2008-10-24       Impact factor: 1.303

Review 9.  The role of microRNA in castration-resistant prostate cancer.

Authors:  William Thieu; Derya Tilki; Ralph de Vere White; Christopher P Evans
Journal:  Urol Oncol       Date:  2014-07       Impact factor: 3.498

10.  miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation.

Authors:  Michela Garofalo; Gianpiero Di Leva; Giulia Romano; Gerard Nuovo; Sung-Suk Suh; Apollinaire Ngankeu; Cristian Taccioli; Flavia Pichiorri; Hansjuerg Alder; Paola Secchiero; Pierluigi Gasparini; Arianna Gonelli; Stefan Costinean; Mario Acunzo; Gerolama Condorelli; Carlo Maria Croce
Journal:  Cancer Cell       Date:  2009-12-08       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.